TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18207532

Group type: COMPARATOR
Intervention: Preoperative only protocol (single dose of cefazolin IV)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Preoperative with extended postoperative antibiotic protocol (single dose of cefazolin IV followed by cefazolin IV every 8 hours for 3 days and oral cephalexin every 6 hours for 7 days)
Number of subjects: 233
Study: 16398845

Group type: EXPERIMENTAL
Intervention: Physiotherapy group (chest wall percussion and oropharyngeal suctioning)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (suctioning without percussion unless indicated)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Physiotherapy group
Number of subjects: 177
Study: 14728188

Group type: EXPERIMENTAL
Intervention: Web-based hypertutorials
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional 'Book-on-the-Web' lessons
Number of subjects: 2
Study: 10717780

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 135

Group type: COMPARATOR
Intervention: IUD (control)
Number of subjects: 135
Study: 8877348

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for up to three months
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 15
Study: 1497158

Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg IM
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3862501

Group type: EXPERIMENTAL
Intervention: Natural Nashers programme (intervention group, n=35)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 73
Study: 31672146

Group type: EXPERIMENTAL
Intervention: liraglutide 3 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 28498233

Group type: EXPERIMENTAL
Intervention: Wearable activity monitor (WAM) in addition to supervised exercise programs (SEPs)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Supervised exercise programs (SEPs) only
Number of subjects: 37
Study: 27028914

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg daily
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg daily
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study: 25300286

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: NPH insulin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oral medication
Number of subjects: 55
Study: 20565216

Group type: EXPERIMENTAL
Intervention: Survival processing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moving scenario
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pleasantness scenario
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Categorized lists
Number of subjects: 0

Group type: COMPARATOR
Intervention: DRM-like word lists
Number of subjects: 0
Study: 16358844

Group type: EXPERIMENTAL
Intervention: Corrective surgery of the nasal obstruction
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 52
Study: 12399209

Group type: EXPERIMENTAL
Intervention: Meningococcal A/C plain polysaccharide vaccine (Mps)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Meningococcal A/C polysaccharide-diphtheria toxoid conjugate vaccine (Mcj)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (unvaccinated subjects)
Number of subjects: 195
Study: 9120384

Group type: EXPERIMENTAL
Intervention: Direct test (cued recall word-stem completion)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Indirect test (repetition priming word-stem completion)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Direct and indirect assessments
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Final free recall test
Number of subjects: 2
Study: 7838584

Group type: EXPERIMENTAL
Intervention: Ketamine (0.15 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Morphine (0.075 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8
Study: 3202206

Group type: EXPERIMENTAL
Intervention: Metoprolol (0.15 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11485845

Group type: EXPERIMENTAL
Intervention: Topical delta-aminolaevulinic acid (ALA) applied under an occlusive dressing for 5 hours on 64 warts.
Number of subjects: 121

Group type: COMPARATOR
Intervention: Vehicle (control) applied to 57 warts.
Number of subjects: 121
Study: 30015528

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab (Japan substudy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Japan substudy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab and Placebo
Number of subjects: 0
Study: 30333337

Group type: COMPARATOR
Intervention: Chloride liberal intravenous fluids (IVFs) including hydroxyethyl starch (130/0.4) in 0.9% normal saline (Voluven), 0.9% normal saline, and Ringer's lactate
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Chloride restricted intravenous fluids (IVFs) including hydroxyethyl starch (130/0.4) in balanced colloid solution (Volulyte) and balanced salt crystalloid solution (PlasmaLyte A)
Number of subjects: 600
Study: 27224953

Group type: EXPERIMENTAL
Intervention: Facilitated training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Self-guided training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All students
Number of subjects: 48
Study: 24347384

Group type: EXPERIMENTAL
Intervention: Interferon-alpha with or without bevacizumab
Number of subjects: 1381
Study: 22425091

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 160

Group type: COMPARATOR
Intervention: Simple open prostatectomy
Number of subjects: 160
Study: 20148732

Group type: EXPERIMENTAL
Intervention: Pre-endoscopic drink of water containing Gascon and Pronase
Number of subjects: 112

Group type: COMPARATOR
Intervention: Endoscopic flushes of 20-ml aliquots of water containing Gascon, with or without Pronase
Number of subjects: 112

Group type: COMPARATOR
Intervention: Endoscopic flushes of 20-ml aliquots of water
Number of subjects: 112
Study: 17587751

Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg once daily
Number of subjects: 6
Study: 15151912

Group type: EXPERIMENTAL
Intervention: Care home rehabilitation service
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual health and social care (Control)
Number of subjects: 165
Study: 11666127

Group type: EXPERIMENTAL
Intervention: TTFCA (total triterpenic fraction of Centella asiatica) at a dose of 60 mg thrice daily for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9699198

Group type: EXPERIMENTAL
Intervention: Tibolone, 2.5 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE), 0.625 mg/day plus medroxyprogesterone acetate (MPA), 5 mg/day
Number of subjects: 50
Study: 7989632

Group type: EXPERIMENTAL
Intervention: Chloral hydrate syrup (30 mg/Kg) and diazepam solution (0.2 mg/Kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Chloral hydrate syrup (30 mg/Kg) and diphenhydramine HCl (1.5 mg/Kg)
Number of subjects: 26
Study: 2563924

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control
Number of subjects: 348
Study: 4537850

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution as the sole intravenous fluid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three different intravenous solutions to meet all fluid and electrolyte requirements
Number of subjects: 0
Study: 31067371

Group type: EXPERIMENTAL
Intervention: Progesterone (400 mg vaginal suppositories twice daily)
Number of subjects: 4153

Group type: COMPARATOR
Intervention: Placebo (matching vaginal suppositories)
Number of subjects: 4153
Study: 29110696

Group type: EXPERIMENTAL
Intervention: Collagen hemostatic sponge
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Gelatin sponge
Number of subjects: 3
Study: 25919527

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 329

Group type: COMPARATOR
Intervention: Referral
Number of subjects: 329

Group type: COMPARATOR
Intervention: Brief Intervention
Number of subjects: 329
Study: 23662176

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 ppm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled epoprostenol (iPGI2) at 50 ng/kg/min
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) in HFpEF patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled epoprostenol (iPGI2) in HFpEF patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Inhaled epoprostenol (iPGI2)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Combination of iNO and iPGI2
Number of subjects: 19
Study: 21496284

Group type: EXPERIMENTAL
Intervention: Anthracycline-taxane sequence (FE(100)C*3 followed by Docetaxel(100)*3)
Number of subjects: 4149

Group type: COMPARATOR
Intervention: Anthracycline-containing chemotherapy (FE(100)C)
Number of subjects: 4149

Group type: EXPERIMENTAL
Intervention: Biological risk assessment using uPA/PAI-1
Number of subjects: 4149

Group type: COMPARATOR
Intervention: Clinical-pathological algorithm
Number of subjects: 4149
Study: 18273603

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage
Number of subjects: 61

Group type: COMPARATOR
Intervention: Protein beverage
Number of subjects: 61
Study: 16649873

Group type: EXPERIMENTAL
Intervention: bupropion SR
Number of subjects: 362

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 362
Study: 15329203

Group type: EXPERIMENTAL
Intervention: TACE + Interferon (IFN)
Number of subjects: 62

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 62
Study: 11104313

Group type: EXPERIMENTAL
Intervention: Psychosocial treatment alone
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Combined treatment (Medication + Psychosocial treatment)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 579

Group type: COMPARATOR
Intervention: Routine community care
Number of subjects: 579
Study: 9195505

Group type: EXPERIMENTAL
Intervention: CAMPATH-1H (C1H) 0.5 mg subcutaneously twice per week
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CAMPATH-1H (C1H) 1.0 mg subcutaneously twice per week
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CAMPATH-1H (C1H)
Number of subjects: 10
Study: 8338919

Group type: EXPERIMENTAL
Intervention: Bumetanide (B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bumetanide plus volume replacement (B + VR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus 100-mmol NaCl load (P + NaCl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bumetanide plus volume replacement plus 100-mmol NaCl load (B + VR + NaCl)
Number of subjects: 0
Study: 2878275

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 19

Group type: COMPARATOR
Intervention: No acupuncture (control group)
Number of subjects: 19
Study: 30371745

Group type: EXPERIMENTAL
Intervention: Proposed cumulative incidence regression models for dynamic treatment regimens (DTRs)
Number of subjects: 0
Study: 30518052

Group type: EXPERIMENTAL
Intervention: n-3 supplementation (2g/day of DHA + EPA)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556
Study: 26709136

Group type: EXPERIMENTAL
Intervention: G‐CSF and Sitagliptin (GS)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 24401769

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 93
Study: 22035368

Group type: EXPERIMENTAL
Intervention: Music intervention (listening to chosen music for 30 minutes per week for 8 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 50
Study: 21106941

Group type: EXPERIMENTAL
Intervention: rostafuroxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: hydrochlorothiazide
Number of subjects: 0
Study: 18364361

Group type: EXPERIMENTAL
Intervention: Brief Alcohol Screening and Intervention for College Students (BASICS)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 145
Study: 15811208

Group type: EXPERIMENTAL
Intervention: Daily ibandronate (2.5 mg)
Number of subjects: 2946

Group type: EXPERIMENTAL
Intervention: Intermittent ibandronate (20 mg every other day for 12 doses every 3 months)
Number of subjects: 2946

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2946
Study: 12432670

Group type: EXPERIMENTAL
Intervention: Exercised with music
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercised without music
Number of subjects: 30
Study: 10383833

Group type: EXPERIMENTAL
Intervention: MP+PGE1
Number of subjects: 275

Group type: COMPARATOR
Intervention: CS+PGE1
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: VER, TFP, PAP, MAN (MP)
Number of subjects: 275

Group type: COMPARATOR
Intervention: VER, TFP, PAP (CS)
Number of subjects: 275
Study: 7675622

Group type: EXPERIMENTAL
Intervention: Cognitive condition where children were informed that the armchair could move
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cognitive condition where children were informed that the armchair could not move
Number of subjects: 40
Study: 2252195

Group type: EXPERIMENTAL
Intervention: Background infusion of ketamine, midazolam, and alfentanil with inhalation of isoflurane in oxygen-enriched air
Number of subjects: 0
Study: 6997513

Group type: EXPERIMENTAL
Intervention: BCG treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (standard surgical therapy)
Number of subjects: 37
Study: 31087060

Group type: EXPERIMENTAL
Intervention: ENFORCE prediction model
Number of subjects: 4036

Group type: COMPARATOR
Intervention: ACCORD trial standard glycemic arm
Number of subjects: 4036
Study: 28556775

Group type: EXPERIMENTAL
Intervention: Ketamine administration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 24
Study: 26159634

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 246
Study: 23441738

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (heavy marcaine)
Number of subjects: 36

Group type: COMPARATOR
Intervention: General anesthesia (propofol + nitric oxide)
Number of subjects: 36
Study: 21421809

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study: 19835754

Group type: EXPERIMENTAL
Intervention: Immediate implant placement and provisionalization
Number of subjects: 76

Group type: COMPARATOR
Intervention: Delayed implant placement with socket grafting followed by provisionalization after 4 months
Number of subjects: 76
Study: 17360317

Group type: EXPERIMENTAL
Intervention: Social support, self-efficacy, and optimism assessed prior to BMT
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Controlling for age, gender, maximum grade of acute GVHD, and treatment arm
Number of subjects: 87
Study: 15541449

Group type: EXPERIMENTAL
Intervention: Mohs' micrographic surgery (MMS)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Surgical excision (SE)
Number of subjects: 408
Study: 11719353

Group type: EXPERIMENTAL
Intervention: G-BM
Number of subjects: 57

Group type: COMPARATOR
Intervention: G-PBSC
Number of subjects: 57
Study: 9141149

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7968073

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study: 3311138

Group type: EXPERIMENTAL
Intervention: Treatment for IGT
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 216
Study: 2619026

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride (Difflam) spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 4623748

Group type: EXPERIMENTAL
Intervention: disodium cromoglycate (DSCG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 29958055

Group type: EXPERIMENTAL
Intervention: 300,000 IU vitamin D3
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1 ml normal saline (placebo)
Number of subjects: 90
Study: 28061962

Group type: EXPERIMENTAL
Intervention: Multireader, multicenter studies
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Randomized controlled trial
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Preclinical technical equivalence trial
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 201
Study: 25214516

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 65

Group type: COMPARATOR
Intervention: No study treatment (Control)
Number of subjects: 65
Study: 23392966

Group type: EXPERIMENTAL
Intervention: Apatite-coated magnetite nanoparticles, injected intravenously or intraperitoneally at doses ranging from 100 to 2,500 mg/Kg.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apatite-coated magnetite nanoparticles, size 8 ± 2 nm.
Number of subjects: 0
Study: 22004767

Group type: EXPERIMENTAL
Intervention: Group based education, physiotherapy and peer support sessions, plus telephone contacts from T2DM volunteers
Number of subjects: 177

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Group based education, physiotherapy and peer support sessions
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Group based education, physiotherapy and peer support sessions for IFG participants
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Group based education, physiotherapy and peer support sessions with longer follow-up (≥ 4 months)
Number of subjects: 177
Study: 19280324

Group type: EXPERIMENTAL
Intervention: CRA13 administered in fed state
Number of subjects: 0

Group type: COMPARATOR
Intervention: CRA13 administered in fasted state
Number of subjects: 0
Study: 16911547

Group type: EXPERIMENTAL
Intervention: Enhanced multidisciplinary care teams
Number of subjects: 1538
Study: 15636272

Group type: EXPERIMENTAL
Intervention: Triazolam (one weight-based dose administered 60 minutes prior to treatment)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Triazolam with supplemental dosage (half the initial dose)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Triazolam augmented with nitrous oxide/oxygen mixtures (30-50%)
Number of subjects: 188
Study: 11385379

Group type: EXPERIMENTAL
Intervention: Sandwich operation (without cardiopulmonary bypass)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (control group)
Number of subjects: 150
Study: 9265911

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3500
Study: 8501567

Group type: EXPERIMENTAL
Intervention: High-titer Edmonston-Zagreb (EZ) measles vaccine
Number of subjects: 384

Group type: COMPARATOR
Intervention: Inactivated poliomyelitis vaccine and standard Schwarz vaccine
Number of subjects: 384
Study: 3325185

Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated mosquito nets
Number of subjects: 4

Group type: COMPARATOR
Intervention: Unimpregnated mosquito nets
Number of subjects: 4
Study: 30202998

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) alone or in combination with vitamin E
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination of CoQ10 and Vitamin E
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 28566022

Group type: EXPERIMENTAL
Intervention: Recovery-Oriented Cognitive Therapy (CT-R)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 60
Study: 26492115

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 52
Study: 23438670

Group type: EXPERIMENTAL
Intervention: Gefitinib 500mg oral daily until progression or severe toxicity
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 29
Study: 21942354

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort SMART)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Conventional best practice (CBP)
Number of subjects: 654
Study: 18469236

Group type: EXPERIMENTAL
Intervention: 250 mg/d EPA + DHA esterified to phospholipid (PL-n-3) (300 mg/d phosphatidylserine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16484911

Group type: EXPERIMENTAL
Intervention: Enteral diet supplemented with eicosapentaenoic acid (EPA) and gamma-linolenic acid (GLA) for 14 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard isonitrogenous, isocaloric enteral diet
Number of subjects: 100
Study: 14602741

Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasonography (CDU)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Gray-scale ultrasonography (GSU)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Radionuclide imaging (RI)
Number of subjects: 11
Study: 10337210

Group type: EXPERIMENTAL
Intervention: French cassoulet (CASS) 22.5 g/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: International sauerkraut (CHOU) 22.5 g/kg
Number of subjects: 8